Merck shares climbed 1.92% in the most recent session, outpacing a 0.6% drop in the broader pharmaceutical index. This marks the second consecutive day of gains, following a 1.35% rise in the prior session. Trading volume exceeded the 30-day average by 12%, signaling strong institutional interest. Analysts point to renewed confidence in Merck’s late-stage oncology pipeline as a driver of the rally.

Merck has become one of the most tracked names on leading research platforms, with weekly search volumes up 45% month-over-month. Sixteen of 20 analysts covering the stock maintain a “buy” or “outperform” rating, and two recent note revisions reflect target price increases of 5–7%. Options activity has also picked up, with call open interest for March expirations up 28% over the past week.

For the quarter ended December 2025, consensus revenue estimates stand at $14.7 billion, up roughly 3.5% year-over-year, while EPS forecasts of $1.85 imply a 9% improvement over prior-year results. Analysts expect gross margins to expand to approximately 78.5%, driven by strong sales of Merck’s flagship oncology franchise and cost-efficiency measures. Fourteen analysts have raised their quarterly EPS estimates in the past month, underscoring growing confidence in the company’s near-term outlook.